Sbi Securities Co., Ltd. Protalix Bio Therapeutics, Inc. Transaction History
Sbi Securities Co., Ltd.
- $3.48 Trillion
- Q2 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 200 shares of PLX stock, worth $328. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 50
300.0%
Holding current value
$328
Previous $128,000
131.25%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
81Shares Held
10MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.95 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.58 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.41 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.36 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$1.12 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $81.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...